Literature DB >> 20537206

Risk factors associated with dizziness during treatment of mucosal leishmaniasis with meglumine antimoniate: 16-year retrospective study of cases from Rio de Janeiro, Brazil.

M H Araujo-Melo1, A M Meneses, A O Schubach, J S Moreira, F Conceição-Silva, M M Salgueiro, M I F Pimentel, M Araújo-Silva, R V C Oliveira, C N Carmo, C M Valete-Rosalino.   

Abstract

OBJECTIVE: To evaluate dizziness in patients receiving meglumine antimoniate for the treatment of mucosal leishmaniasis.
MATERIALS AND METHODS: We retrospectively studied 127 patients treated at the Laboratory of Leishmaniasis Surveillance, Evandro Chagas Clinical Research Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil, between 1 January 1989 and 31 December 2004.
RESULTS: A low dose of meglumine antimoniate (5 mg/kg/day) was used in 86.6 per cent of patients; a dose of 10 mg/kg/day or higher was used in 13.4 per cent of patients. Dizziness was reported by 4.7 per cent of patients. The adjusted odds ratios were 7.37 for dizziness in female patients, 4.9 for dizziness in patients aged 60 years or older, and 7.77 for dizziness in the presence of elevated serum lipase.
CONCLUSION: We suggest that dizziness may be a side effect of meglumine antimoniate, particularly in elderly individuals, in females and in patients with elevated serum lipase.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20537206     DOI: 10.1017/S0022215110001325

Source DB:  PubMed          Journal:  J Laryngol Otol        ISSN: 0022-2151            Impact factor:   1.469


  4 in total

1.  Age modifies the immunologic response and clinical presentation of American tegumentary leishmaniasis.

Authors:  Augusto M Carvalho; Camila F Amorim; Juliana L S Barbosa; Alexsandro S Lago; Edgar M Carvalho
Journal:  Am J Trop Med Hyg       Date:  2015-04-27       Impact factor: 2.345

2.  First report on ototoxicity of meglumine antimoniate.

Authors:  Cláudia Maria Valete-Rosalino; Maria Helena Araujo-Melo; Débora Cristina de Oliveira Bezerra; Renata Oliveira de Barcelos; Vanessa de Melo-Ferreira; Tânia Salgado de Sousa Torraca; Ana Cristina da Costa Martins; João Soares Moreira; Mirian Catherine Melgares Vargas; Frederico Pereira Bom Braga; Mariza de Matos Salgueiro; Maurício Naoto Saheki; Armando Oliveira Schubach
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2014 Sep-Oct       Impact factor: 1.846

3.  In Vitro Anti-Leishmanial Effect of Metallic Meso-Substituted Porphyrin Derivatives against Leishmania braziliensis and Leishmania panamensis Promastigotes Properties.

Authors:  Fabian Espitia-Almeida; Carlos Díaz-Uribe; William Vallejo; Doris Gómez-Camargo; Arnold R Romero Bohórquez
Journal:  Molecules       Date:  2020-04-19       Impact factor: 4.411

4.  Meglumine antimoniate was associated with a higher cure rate than liposomal amphotericin B in the treatment of American tegumentary leishmaniasis: A retrospective cohort study from a Leishmania braziliensis-endemic area.

Authors:  Daniel Holanda Barroso; Renata Trindade Gonçalves; Joadyson Silva Barbosa; Jorgeth de Oliveira Carneiro da Motta; Gustavo Subtil Magalhães Freire; Ciro Martins Gomes; Raimunda Nonata Ribeiro Sampaio
Journal:  Front Cell Infect Microbiol       Date:  2022-09-23       Impact factor: 6.073

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.